2024年8月15日，科伦药业获华福证券买入评级，近一个月科伦药业获得2份研报关注。
研报预计，公司2024-2026年收入增速分别为10%/10%/9%，归母净利润增速分别为19%/14%/15%。研报认为，科伦药业在大输液领域及抗生素中间体领域的龙头地位，以及未来ADC等创新药管线上市等带来的业绩高增长性。
风险提示：集采降价风险；行业政策变革风险；产品研发及上市不及预期的风险；产品销售不及预期的风险。
科伦药业获华福证券买入评级，三发驱动，发展驶入快车道
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha